-
AstraZeneca refused interim injunction on SPC for blockbuster diabetes treatment against Glenmark but swiftly obtains permission to appeal
08 Apr 2025 17:35 GMT
… of its type 2 diabetes treatment, Forxiga® (dapagliflozin) for … to the ability of pharmaceutical companies to obtain interim … however, that in the rivaroxaban case, generics were only … Damages are an adequate remedy for AstraZeneca should the interim …
-
Electronic Monitoring of Medication Adherence to Direct Oral Anticoagulants: A Systematic Review
07 Apr 2025 17:08 GMT
… ”, “rivaroxaban”, “DOAC”, “NOAC”; topic (3) comprised “patient monitoring”, “drug monitoring”, “electronic monitoring”, “medication … DOACs treatment was mostly conducted using smart pill bottles to track medication adherence …
-
RIVAWAR: Rivaroxaban Akin to Warfarin for Left Ventricular Thrombus After MI
05 Apr 2025 00:22 GMT
… , non-inferiority, randomized controlled RIVAWAR trial, presented at the American College … 261 patients in Pakistan to treatment with rivaroxaban or warfarin for three … frequent blood test monitoring. Concomitant medication use and diet interactions can …
-
The Changing Landscape of Heart Failure Drug Clinical Trials in China, 2013–2023
03 Apr 2025 11:17 GMT
… neprilysin inhibitor (ARNI), and rivaroxaban (n=42), a factor … Drugs
The field of HF drug trials has focused predominantly on chemical drugs. Chinese pharmaceutical … Medical Doctor Association; et al. Chinese guidelines for the diagnosis and treatment …
-
Q1 2025 Recap: Cardiology News and Updates
08 Apr 2025 17:27 GMT
… Anticoagulants, including rivaroxaban, are commonly … FDA approved the supplemental New Drug Application (sNDA) for vutrisiran (AMVUTTRA) for treatment … Milsetone Pharmaceuticals.
Q1 2025 Trial Announcements … Medicine, tackled a pair of late-breaking trials …
-
RyCarma Therapeutics Appoints Elizabeth Tarka, M.D., as Chief Medical Officer
02 Apr 2025 11:23 GMT
… and medical oversight of late-stage clinical trials makes … experience in the pharmaceutical and biotechnology industry. She … for Xarelto® (rivaroxaban) at Janssen Pharmaceuticals and spent over … not addressed by existing treatment options.”
Dr. Tarka …
-
Coagulation Market Size Set to Reach USD 10.85 Billion by 2030, Driven by Rising Blood Disorder Cases and Advancements in Treatment Technologies - The Insight Partners
01 Apr 2025 14:41 GMT
… Genrui Biotech Co., Ltd.; Transasia Bio-Medicals … , Blood Disorder Treatment Market, among … apixaban, and rivaroxaban in countries recognizing … pharmaceutical manufacturers, contract research and manufacturing organizations, healthcare providers, and medical …
-
FDA News Month in Review: March 2025
31 Mar 2025 20:32 GMT
… trials, which demonstrated the efficacy of low-dose rivaroxaban … 20, 2025, Johnson & Johnson announced FDA approval of guselkumab … Pharmaceuticals'; etripamil nasal spray (Cardamyst) for the treatment of … concerns regarding the drug';s clinical safety …
-
Rivaroxaban shown to be a viable alternative to warfarin for left ventricular thrombus
30 Mar 2025 14:23 GMT
… received standard treatment with warfarin, an older blood-thinning drug. The findings … , of 2-3). Many other medications and foods can interact with … of rivaroxaban as a viable alternative to warfarin for the treatment of …
-
Rivaroxaban a ‘viable alternative’ to warfarin for blood clots after heart attack
29 Mar 2025 22:58 GMT
… many foods and other medications. Direct oral anticoagulants have … controlled trial designed to evaluate efficacy and safety of rivaroxaban … when it comes to treatment of thrombotic events, the … et al. Late-breaking clinical trials II. Presented at: American …